A Study to Investigate the Efficacy of AlphaWave® L-Theanine on Stress
A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Investigate the Efficacy of an Acute Dose of AlphaWave® LTheanine on Stress in a Healthy Adult Population
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A5R8
- KGK Science Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females between 18 and 65 years of age, inclusive
- BMI between 18.5 to 29.9 kg/m2, inclusive
- Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, total endometrial ablation) or have been post-menopausal for at least 1 year prior to screening OR,
Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
- Intrauterine devices
- Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Individuals with moderate stress as determined by the Perceived Stress Scale (scores ranging from 14 - 26 are considered moderate stress)
- Have a regular sleep-wake cycle with a bedtime between 9:00 pm and 12:00 am and receive between 7 and 9 hours of sleep for at least 3 weeks prior to baseline
- Agrees to maintain current sleep schedule throughout study
- Agrees to maintain current levels of diet, supplements, and exercise until the end of the study
- Agrees to refrain from exercising 24-hours prior to the visits
- Agrees to abstain from using hair products on the day of visits
- Willingness to complete questionnaires, records, diaries associated with the study, and to complete all clinic visits
- Healthy as determined by medical history, laboratory results, and physical exam as assessed by the QI
Exclusion Criteria:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
- Clinically significant abnormal laboratory results at screening as assessed by the QI
- Participants who have a known allergy to the test material's active or inactive ingredients
- Current employment that calls for rotating shift work or shift work that will disrupt normal circadian rhythm or have worked shift work in the last 3 weeks
- Travelled across 1 or more time zones in the last 3 weeks and/or is anticipating more travel
- Self reported epilepsy and/or seizures
- Type I or Type II Diabetes
- Unstable metabolic disease or chronic diseases as assessed by the QI
- Current or history of any significant disease of the gastrointestinal tract
- Hypertension treated with medication or supplements or untreated hypertension
- Self reported anxiety or depression
- Significant cardiovascular event in the past 6 months as assessed by the QI
- Major surgery in the past 3 months or individuals who have planned surgery during the course of the trial. Participants with minor surgery will be considered on a case-by-case basis by the QI
- Individuals with an autoimmune disease or are immune-compromised
- History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones symptom-free for 6 months
- Self reported current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Self reported confirmation of medical or neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation
- Self reported blood/bleeding disorders that will have an effect on safety outcomes as assessed by the QI
- Alcohol or drug abuse within the last 12 months
- High alcohol intake (>2 standard drinks per day)
- Use of medicinal cannabinoid products
- Chronic use of cannabinoid products (>2 times/week). Occasional use to be assessed by the QI on a case by case basis
- Use of tobacco and nicotine-containing products within 60 days of baseline
- Current use of prescribed medications listed: antibiotics, antiepileptics, antiseizure medications, sedatives, hypnotics
- Current use of over-the-counter medications, supplements, foods, and/or drinks listed: caffeine, green tea, L-theanine supplements, melatonin supplements, valerian root supplements, GABA supplements, tart cherries/drinks/supplements, amla, ashwagandha, rhodiola, shatavari, ginseng
- Blood donation 30 days prior to screening or a planned donation 30-days of the last study visit
- Participants in a clinical research trial within 30 days of screening
- Individuals who are unable to give informed consent
- Any other condition that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
microcrystalline cellulose
|
|
EXPERIMENTAL: AlphaWave® LTheanine
|
200 mg of AlphaWave® LTheanine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change in salivary cortisol levels from pre- to post-tests between AlphaWave® LTheanine versus placebo.
Time Frame: 9 days
|
Assessed by analysis of saliva sample at baseline and end of study
|
9 days
|
|
The change in EEG total alpha wave readings from pre- to post-tests between AlphaWave® LTheanine versus placebo.
Time Frame: 9 days
|
Measured and analyzed at baseline and end of study
|
9 days
|
|
The change in EEG frontal alpha wave readings from pre- to post-tests between AlphaWave® LTheanine versus placebo.
Time Frame: 9 days
|
Measured and analyzed at baseline and end of study
|
9 days
|
|
The change in EEG midline theta wave readings from pre- to post-tests between AlphaWave® LTheanine versus placebo.
Time Frame: 9 days
|
Measured and analyzed at baseline and end of study
|
9 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change in heart rate from pre-to post-test between the investigational product versus placebo
Time Frame: 9 days
|
Measured at baseline and end of study
|
9 days
|
|
The change in blood pressure from pre- to post-test between the investigational product versus placebo
Time Frame: 9 days
|
Measured at baseline and end of study
|
9 days
|
|
The change in State-Trait Anxiety Inventory (STAI) from pre- to post-test between the investigational product versus placebo
Time Frame: 9 days
|
Assessed by the participants' answers to the questionnaire
|
9 days
|
|
The change in Visual Analog Scale (VAS) from pre- to post-tests between the investigational product versus placebo
Time Frame: 9 days
|
Assessed by the participants' answers to the questionnaire
|
9 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Mal Evans, PhD, KGK Science Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 19LSHE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.